Longevity research has propelled the scientific community to concentrate on interventions that do more than simply add years to life ...
Regarding our CD38-SADA Phase 1 trial ... Same thing, you start looking at liver enzymes to determine if you're actually having an impact. Because systemic radiotherapy at these relatively ...
summarized the role of extracellular vesicles containing ectonucleotidases and other purine-metabolizing enzymes involved in purinergic signaling. An original article by Zubiar et al. focused on the ...
Alexa Fluor®-700 anti-mouse CD38 antibody was obtained from eBioscience (San Diego ... Insulin in serum was performed by enzyme-linked immunosorbent assay (ELISA) (RayBiotech, Norcross, GA, United ...
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...
Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...
While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...
Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...
Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results